Introduction
============

Orgaran^®^(danaparoid sodium) is a low-molecular-weight, nonheparin glycosaminoglycan antithrombotic that is currently a first-line treatment for heparin-induced thrombocytopenia (HIT). This study reports on the safety of Orgaran^®^in ICU patients suffering from HIT and acute renal failure requiring continuous renal replacement therapy (haemofiltration).

Methods
=======

Data on 96 case reports from personal experience and publications have been collated.

Results
=======

Nineteen females and 59 males (18 unknown gender) with a median age of 60 years (range 22--95 years) presented with a variety of clinical problems that either preceded or complicated their HIT; for example, postoperative/accidental trauma or overt bleeding in 61, sepsis/septicaemia/septic shock in 37, thromboembolism in 23, multiple organ dysfunction syndrome in 14, disseminated intravascular coagulation in eight and other miscellaneous serious problems in 38.

A variety of continuous extracorporeal haemofiltration circuits was used for from 1 to 39 days (median 7 days). The Orgaran^®^dosing schedule was usually initiated with a 2,000--2,500 U intravenous bolus injection. After two step-down dose periods the subsequent maintenance infusion was usually titrated according to each patient\'s thromboembolic and bleeding risk status. Hence most patients received 100--400 U/hour, but 11 patients required up to 600 U/hour temporarily to control extracorporeal circuit clotting.

There were 12 minor bleeding events, occurring mostly during the maintenance infusion rate adjustment period and which responded to transient interruption and/or lowering of the infusion rate. Eleven nonfatal major bleeding events occurred (four due to procedural errors) and eight fatal major bleeds, two of which occurred 3 days and 8 days after Orgaran^®^discontinuation.

Plasma anti-FXa levels were reported for 38 patients. During seven of the eight fatal bleeding episodes the plasma anti-FXa levels were ≥0.8 U/ml in three patients and 0.31--0.66 U/ml (that is, within the target range) in the other four patients. The highest anti-FXa response of 2.00 U/ml was associated with minor bleeding from an angiomatous malformation and stopped when the Orgaran^®^dose was reduced. However, of the 11 patients receiving \>400 U/hour, four suffered major bleeding (three fatal) and two developed minor bleeding. Most of these patients received continuous arterio-venous haemodiafiltration treatment, which may have been a contributory factor.

Conclusion
==========

We recommend that maintenance Orgaran^®^infusion rates ≥400 U/hour should be avoided unless serious circuit clotting is grossly affecting the haemofilter life. The infusion rate should be monitored clinically; that is, on the basis of bleeding and circuit clotting rather than the patients\' plasma anti-FXa responses.
